AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2191876 — intervention group
Group type: EXPERIMENTAL
Intervention: General anaesthesia (nitrous oxide, fentanyl, isoflurane with skin infiltration containing 200 micrograms adrenaline)
Number of subjects: 75
Study 2191876 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia without skin infiltration
Number of subjects: 75
Study 2191876 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anaesthesia
Number of subjects: 75
Study 2191876 — intervention group
Group type: EXPERIMENTAL
Intervention: General anaesthesia with skin infiltration
Number of subjects: 75
Study 2191876 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 75
Study 511803 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback for accuracy of blood pressure discriminations
Number of subjects: 17
Study 511803 — intervention group
Group type: COMPARATOR
Intervention: Feedback withdrawal condition in Group I
Number of subjects: 17
Study 31760174 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care intervention
Number of subjects: 74
Study 31760174 — intervention group
Group type: COMPARATOR
Intervention: Comparison condition (control)
Number of subjects: 74
Study 31377269 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylnaltrexone (0.3 mg/kg intravenous)
Number of subjects: 30
Study 31377269 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 28127644 — intervention group
Group type: EXPERIMENTAL
Intervention: Far Infrared Radiation (FIR) treatment
Number of subjects: 32
Study 25438232 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline resting heart rate (RHR)
Number of subjects: 1563
Study 25438232 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-varying resting heart rate (RHR)
Number of subjects: 1563
Study 23613255 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group with dietary counseling introduced in infancy and maintained until 20 years of age.
Number of subjects: 394
Study 23613255 — intervention group
Group type: COMPARATOR
Intervention: Intervention adolescents compared to control group.
Number of subjects: 394
Study 23613255 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group with dietary counseling.
Number of subjects: 394
Study 23613255 — intervention group
Group type: COMPARATOR
Intervention: Adolescents with low number of metrics (≤3) compared to those with higher score.
Number of subjects: 394
Study 21713728 — intervention group
Group type: EXPERIMENTAL
Intervention: Bonfils Intubation Fiberscope
Number of subjects: 80
Study 21713728 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscopy
Number of subjects: 80
Study 18809226 — intervention group
Group type: EXPERIMENTAL
Intervention: Triplet therapy with third generation cytotoxic drugs (paclitaxel, docetaxel, vinorelbine, gemcitabine)
Number of subjects: 1932
Study 18809226 — intervention group
Group type: EXPERIMENTAL
Intervention: Triplet therapy with third generation cytotoxic drugs
Number of subjects: 1932
Study 18809226 — intervention group
Group type: COMPARATOR
Intervention: Double therapy (standard double therapy)
Number of subjects: 1932
Study 16385331 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium treatment
Number of subjects: 80
Study 16385331 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 80
Study 12709466 — intervention group
Group type: EXPERIMENTAL
Intervention: Established intervention (n = 268)
Number of subjects: 810
Study 12709466 — intervention group
Group type: EXPERIMENTAL
Intervention: Established plus DASH intervention (n = 269)
Number of subjects: 810
Study 12709466 — intervention group
Group type: COMPARATOR
Intervention: Advice only group (n = 273)
Number of subjects: 810
Study 10755536 — intervention group
Group type: EXPERIMENTAL
Intervention: tacrolimus + azathioprine (AZA)
Number of subjects: 223
Study 10755536 — intervention group
Group type: EXPERIMENTAL
Intervention: cyclosporine (Neoral) + mycophenolate mofetil (MMF)
Number of subjects: 223
Study 10755536 — intervention group
Group type: EXPERIMENTAL
Intervention: tacrolimus + mycophenolate mofetil (MMF)
Number of subjects: 223
Study 10755536 — intervention group
Group type: EXPERIMENTAL
Intervention: tacrolimus
Number of subjects: 223
Study 8610867 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol group (n = 15) received 3 mL of 1.5% lidocaine with 3 micrograms isoproterenol intravenously.
Number of subjects: 30
Study 8610867 — intervention group
Group type: COMPARATOR
Intervention: Saline group (n = 15) received 3 mL of normal saline.
Number of subjects: 30
Study 1420744 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyethylene glycol
Number of subjects: 59
Study 1420744 — intervention group
Group type: COMPARATOR
Intervention: Sodium picosulphate
Number of subjects: 59
Study 6093241 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime (1 g i.m. every 12 hours to a total of 3 g)
Number of subjects: 96
Study 6093241 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antibiotic)
Number of subjects: 96
Study 6093241 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime
Number of subjects: 96
Study 6093241 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 96
Study 31451009 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention with a low-saturated-fat diet, reduced-energy intake, functional foods, and physical activity for 15 days.
Number of subjects: 1065
Study 31451009 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention with a low-saturated-fat diet, reduced-energy intake, functional foods, and physical activity for 75 days.
Number of subjects: 1065
Study 31451009 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle intervention (randomized control-placebo study).
Number of subjects: 1065
Study 30053849 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Dental Wellness Programme (FDWP)
Number of subjects: 478
Study 30053849 — intervention group
Group type: COMPARATOR
Intervention: Standard MOH programme
Number of subjects: 478
Study 27460054 — intervention group
Group type: EXPERIMENTAL
Intervention: Solar-powered mosquito trapping system
Number of subjects: 0
Study 24703832 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive exercise programme (20 sessions)
Number of subjects: 172
Study 24703832 — intervention group
Group type: COMPARATOR
Intervention: Advice (one session and telephone support)
Number of subjects: 172
Study 22682298 — intervention group
Group type: EXPERIMENTAL
Intervention: Health coaching by telephony
Number of subjects: 1221
Study 22682298 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1221
Study 21034160 — intervention group
Group type: EXPERIMENTAL
Intervention: Maitake mushroom extract (MSX)
Number of subjects: 80
Study 21034160 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene citrate (CC)
Number of subjects: 80
Study 21034160 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of MSX and CC
Number of subjects: 80
Study 16938159 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol 1 mg intravenous
Number of subjects: 93
Study 16938159 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg intravenous
Number of subjects: 93
Study 16938159 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 16602440 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum copper concentration in RA patients (19.1 +/- 4.5 micromol/L)
Number of subjects: 58
Study 16602440 — intervention group
Group type: EXPERIMENTAL
Intervention: Hair copper concentration in RA patients (14.3 +/- 4.2 microg/g dry mass)
Number of subjects: 58
Study 16602440 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythrocyte copper concentration in RA patients (67.6 +/- 13.4 microg/dL)
Number of subjects: 58
Study 16602440 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of mean serum copper concentration with erythrocyte sedimentation rate
Number of subjects: 58
Study 16602440 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of mean serum copper concentration with Ritchie articular index
Number of subjects: 58
Study 16602440 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of mean serum copper concentration with hemoglobin
Number of subjects: 58
Study 12379846 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-aggregated Abeta42 vaccination (primary injection followed by booster injection)
Number of subjects: 0
Study 12379846 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11482144 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser irradiation (5 W, 20 Hz) with K‐files and laterally condensed gutta‐percha and Pulp Canal Sealer EWT
Number of subjects: 40
Study 11482144 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser irradiation (5 W, 20 Hz) with ProFiles and vertically condensed gutta‐percha and Pulp Canal Sealer EWT
Number of subjects: 40
Study 11482144 — intervention group
Group type: COMPARATOR
Intervention: Control group (no laser irradiation) with K‐files and laterally condensed gutta‐percha and Pulp Canal Sealer EWT
Number of subjects: 40
Study 11482144 — intervention group
Group type: COMPARATOR
Intervention: Control group (no laser irradiation) with ProFiles and vertically condensed gutta‐percha and Pulp Canal Sealer EWT
Number of subjects: 40
Study 9627891 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular implant-supported overdentures
Number of subjects: 102
Study 9627891 — intervention group
Group type: COMPARATOR
Intervention: Conventional dentures
Number of subjects: 102
Study 7936862 — intervention group
Group type: EXPERIMENTAL
Intervention: Measles-mumps-rubella-varicella vaccine
Number of subjects: 149
Study 3129741 — intervention group
Group type: EXPERIMENTAL
Intervention: Mupirocin applied topically 3 times a day for 5 days
Number of subjects: 98
Study 3129741 — intervention group
Group type: COMPARATOR
Intervention: Placebo applied topically 3 times a day for 5 days
Number of subjects: 98
Study 29350603 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision tree models for predicting outcomes
Number of subjects: 548
Study 29350603 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision tree models for predicting survival on day 1
Number of subjects: 548
Study 29350603 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision tree models for predicting favorable functional outcome
Number of subjects: 548
Study 29350603 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision tree models for predicting favorable functional outcome at all time points
Number of subjects: 548
Study 29350603 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision tree models for predicting VP shunt dependency
Number of subjects: 548
Study 26895984 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging reminders for influenza vaccination
Number of subjects: 156
Study 26895984 — intervention group
Group type: COMPARATOR
Intervention: Standard care (no text messaging reminders)
Number of subjects: 156
Study 26182760 — intervention group
Group type: EXPERIMENTAL
Intervention: URS plus ICL (Group-A)
Number of subjects: 224
Study 26182760 — intervention group
Group type: COMPARATOR
Intervention: ESWL (Group-B)
Number of subjects: 224
Study 23926584 — intervention group
Group type: EXPERIMENTAL
Intervention: All-on-2 implants
Number of subjects: 60
Study 23926584 — intervention group
Group type: COMPARATOR
Intervention: All-on-4 implants
Number of subjects: 60
Study 22241259 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacha inchi oil (2gr/5ml) administered orally at 5 ml for four months
Number of subjects: 24
Study 22241259 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacha inchi oil (2gr/5ml) administered orally at 10 ml for four months
Number of subjects: 24
Study 18279056 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine plus oxaliplatin
Number of subjects: 0
Study 18279056 — intervention group
Group type: COMPARATOR
Intervention: Infusional regimens of 5‐FU +/‐ LV and oxaliplatin
Number of subjects: 0
Study 17015064 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital ECGs
Number of subjects: 433
Study 17015064 — intervention group
Group type: COMPARATOR
Intervention: First hospital ECG
Number of subjects: 433
Study 17015064 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital ECGs in acute coronary syndrome subgroup
Number of subjects: 433
Study 17015064 — intervention group
Group type: COMPARATOR
Intervention: First hospital ECG in acute coronary syndrome subgroup
Number of subjects: 433
Study 12520528 — intervention group
Group type: EXPERIMENTAL
Intervention: ED-71 (0.25, 0.5, 0.75, and 1.0 microgram) administered orally daily for 6 months
Number of subjects: 109
Study 12520528 — intervention group
Group type: EXPERIMENTAL
Intervention: ED-71
Number of subjects: 109
Study 11099743 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg + Clonazepam 0.5-1.0 mg
Number of subjects: 0
Study 11099743 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine 20 mg + Placebo
Number of subjects: 0
Study 8968175 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 2 mg
Number of subjects: 81
Study 8968175 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 4 mg
Number of subjects: 81
Study 8968175 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 8 mg
Number of subjects: 81
Study 8968175 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil alone
Number of subjects: 81
Study 8968175 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 0.05 to 0.1 microgram.kg‐1.min‐1 with 2 mg midazolam
Number of subjects: 81
Study 8968175 — intervention group
Group type: COMPARATOR
Intervention: Light sedation (OAA/S scores of 1 to 3)
Number of subjects: 81
Study 8968175 — intervention group
Group type: COMPARATOR
Intervention: Light sedation with PONV
Number of subjects: 81
Study 1594280 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose midazolam
Number of subjects: 39
Study 1594280 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 39
Study 1594280 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 39
Study 28899651 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher formula intake at 14 months
Number of subjects: 337
Study 28899651 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary diversity at 14 months
Number of subjects: 337
Study 28899651 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal age
Number of subjects: 337
Study 28899651 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal education
Number of subjects: 337
Study 28899651 — intervention group
Group type: EXPERIMENTAL
Intervention: Child Food Neophobia Score
Number of subjects: 337
Study 27029706 — intervention group
Group type: EXPERIMENTAL
Intervention: Trebananib 15 mg/kg QW plus weekly paclitaxel
Number of subjects: 919
Study 27029706 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus weekly paclitaxel
Number of subjects: 919
Study 24882176 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-assisted internet cognitive behavioural treatment (iCBT) program
Number of subjects: 707
Study 23864802 — intervention group
Group type: EXPERIMENTAL
Intervention: D-002 (100 mg/day)
Number of subjects: 50
Study 23864802 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 20495193 — intervention group
Group type: EXPERIMENTAL
Intervention: Local ablation therapies
Number of subjects: 41
Study 20495193 — intervention group
Group type: COMPARATOR
Intervention: Randomized clinical trial participation (no strong preference)
Number of subjects: 41
Study 18511175 — intervention group
Group type: EXPERIMENTAL
Intervention: Alum-containing thermal water
Number of subjects: 40
Study 18511175 — intervention group
Group type: COMPARATOR
Intervention: Tap water
Number of subjects: 40
Study 17024953 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee staining solution
Number of subjects: 45
Study 17024953 — intervention group
Group type: EXPERIMENTAL
Intervention: Red wine staining solution
Number of subjects: 45
Study 17024953 — intervention group
Group type: COMPARATOR
Intervention: Distilled water (control)
Number of subjects: 45
Study 17024953 — intervention group
Group type: EXPERIMENTAL
Intervention: Night Effects bleaching agent
Number of subjects: 45
Study 17024953 — intervention group
Group type: EXPERIMENTAL
Intervention: Simply White Night bleaching agent
Number of subjects: 45
Study 17024953 — intervention group
Group type: EXPERIMENTAL
Intervention: Opalescence Quick bleaching agent
Number of subjects: 45
Study 12773075 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg/d
Number of subjects: 0
Study 12773075 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Number of subjects: 0
Study 11288035 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone (400 mg/d)
Number of subjects: 78
Study 11288035 — intervention group
Group type: COMPARATOR
Intervention: Control group (without troglitazone)
Number of subjects: 78
Study 9060022 — intervention group
Group type: EXPERIMENTAL
Intervention: Various treatments for analgesics
Number of subjects: 3400
Study 8239969 — intervention group
Group type: EXPERIMENTAL
Intervention: Flex Foot
Number of subjects: 9
Study 8239969 — intervention group
Group type: EXPERIMENTAL
Intervention: Seattle Foot
Number of subjects: 9
Study 8239969 — intervention group
Group type: COMPARATOR
Intervention: SACH foot
Number of subjects: 9
Study 3014334 — intervention group
Group type: EXPERIMENTAL
Intervention: BK viruria (excretion of BK virus)
Number of subjects: 53
Study 3014334 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic marrow recipients with BK viruria
Number of subjects: 53
Study 3014334 — intervention group
Group type: COMPARATOR
Intervention: Allogeneic marrow recipients without BK viruria
Number of subjects: 53
Study 3014334 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic marrow recipients
Number of subjects: 53
Study 3014334 — intervention group
Group type: COMPARATOR
Intervention: Syngeneic or autologous marrow recipients
Number of subjects: 53
Study 3014334 — intervention group
Group type: EXPERIMENTAL
Intervention: BK viruria during cystitis episodes
Number of subjects: 53
Study 3014334 — intervention group
Group type: COMPARATOR
Intervention: Cystitis-free periods
Number of subjects: 53
Study 30507230 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation intentions (self-regulation intervention)
Number of subjects: 82
Study 30507230 — intervention group
Group type: COMPARATOR
Intervention: Control group (no implementation intentions)
Number of subjects: 82
Study 27417982 — intervention group
Group type: EXPERIMENTAL
Intervention: Titrated disease management (TDM) strategy with varying intensity levels (low, medium, high) based on SBP control at baseline, 6, and 12 months.
Number of subjects: 385
Study 27417982 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity strategy (control arm) utilizing a licensed practical nurse for bi-monthly, non-tailored behavioral support calls.
Number of subjects: 385
Study 23910952 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm-based treatment with basal-bolus insulin therapy
Number of subjects: 74
Study 23910952 — intervention group
Group type: COMPARATOR
Intervention: Standard glycaemic management
Number of subjects: 74
Study 22397814 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength Training (ST, n=8)
Number of subjects: 49
Study 22397814 — intervention group
Group type: EXPERIMENTAL
Intervention: Recreational Soccer Training (SOC, n=15)
Number of subjects: 49
Study 22397814 — intervention group
Group type: COMPARATOR
Intervention: High-Intensity Interval Running (INT, n=7)
Number of subjects: 49
Study 22397814 — intervention group
Group type: COMPARATOR
Intervention: Continuous Running (RUN, n=9)
Number of subjects: 49
Study 22397814 — intervention group
Group type: COMPARATOR
Intervention: Continuation of an Inactive Lifestyle (CON, n=10)
Number of subjects: 49
Study 20350194 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine (25 mg/kg)
Number of subjects: 83
Study 20350194 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate (3 doses of 4 mg/kg)
Number of subjects: 83
Study 20350194 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine-artesunate (3 doses of 100 mg artesunate plus 250 mg mefloquine)
Number of subjects: 83
Study 20350194 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel (40 mg/kg)
Number of subjects: 83
Study 20350194 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine, Artesunate, Mefloquine-artesunate
Number of subjects: 83
Study 20350194 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel and Mefloquine-artesunate
Number of subjects: 83
Study 18324348 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasieka's parathyroid assessment of symptom scores (PAS)
Number of subjects: 101
Study 18324348 — intervention group
Group type: EXPERIMENTAL
Intervention: SF-36 questionnaire
Number of subjects: 101
Study 18324348 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall analysis of PAS and SF-36
Number of subjects: 101
Study 15904617 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic hysterectomy with vaginal cuff suspension (LHS group)
Number of subjects: 68
Study 15904617 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic hysterectomy without vaginal cuff suspension (LH group)
Number of subjects: 68
Study 12585781 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (EG) - weighted vest walking and strength-training exercises for 32 weeks (three 1-h sessions/week)
Number of subjects: 18
Study 12585781 — intervention group
Group type: COMPARATOR
Intervention: Sedentary control group (CG) - no exercise
Number of subjects: 18
Study 10674832 — intervention group
Group type: EXPERIMENTAL
Intervention: Management of Type 1 diabetes during pregnancy
Number of subjects: 0
Study 10674832 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin therapy
Number of subjects: 0
Study 10674832 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnancy-associated hypertension
Number of subjects: 0
Study 8760238 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid infusion (Vamin 9; Kabi Pharmacia) at 4 ml/min for 210 min
Number of subjects: 21
Study 8760238 — intervention group
Group type: COMPARATOR
Intervention: Control infusion of Hartman's solution at 4 ml/min for 210 min
Number of subjects: 21
Study 1718364 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 20 mg given orally with MST 20 mg
Number of subjects: 0
Study 1718364 — intervention group
Group type: COMPARATOR
Intervention: MST with placebo
Number of subjects: 0
Study 1718364 — intervention group
Group type: EXPERIMENTAL
Intervention: MST with cisapride
Number of subjects: 0
Study 6808542 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking (high nicotine content)
Number of subjects: 0